Loading clinical trials...
Loading clinical trials...
A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma
Conditions
Interventions
Obinutuzumab
Bendamustine
+4 more
Locations
33
United States
Rocky Mountain Cancer Center; Medical Oncology
Boulder, Colorado, United States
American Oncology Partners of Maryland, PA
Bethesda, Maryland, United States
Summit Medical Center
Florham Park, New Jersey, United States
San Juan Oncology Associates
Farmington, New Mexico, United States
Willamette Valley Cancer Ctr - 520 Country Club
Eugene, Oregon, United States
Texas Onc-Central Austin CA Ct
Austin, Texas, United States
Start Date
February 26, 2019
Primary Completion Date
August 4, 2020
Completion Date
January 25, 2023
Last Updated
April 4, 2024
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions